This is a phase 1/2 study of a radio-labeled investigational drug, 225Ac-lintuzumab, given in combination with low-dose cytarabine in previously untreated elderly patients with AML. Phase 1 will establish the MTD of fractionated doses of Lintuzumab-Ac225 in combination with low dose cytosine arabinoside, and Phase 2 will help determine the response rate of these drugs in combination. We anticipate that between 10-15 subjects will participate in this study at UPenn.

You may be eligible for this study if you meet the following criteria:

• Conditions: Acute myeloid leukemia,Leukemia,TBD
• Age: 99 years or below
• Gender: All